Bevacizumab versus ranibizumab: why are we not playing the joker?

Int J Clin Pharm. 2013 Aug;35(4):507-9. doi: 10.1007/s11096-013-9779-7.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Angiogenesis Inhibitors / economics*
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / economics*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Bevacizumab
  • Drug Approval
  • Drug Costs
  • Drug Design
  • Humans
  • Italy
  • Macular Degeneration / drug therapy*
  • Macular Degeneration / economics
  • Macular Degeneration / physiopathology
  • Off-Label Use
  • Ranibizumab

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Ranibizumab